Health and Fitness Health and Fitness
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Alexza to Announce 2012 Second Quarter Financial Results on Wednesday, August 8, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Anthera Pharmaceuticals Announces Exercise in Ful .. and Completion of Public Offering of Common Stock
[ Tue, Jul 24th 2012 ] - Market Wire
Cytokinetics to Announce Second Quarter Results on July 31, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
TPI Provides Progress Update on Qionglai Facility (QLF) Construction
[ Tue, Jul 24th 2012 ] - Market Wire
ABC News Affiliate Airs Segment Describing Implan .. "Company on the Front Lines of Airport Security"
[ Tue, Jul 24th 2012 ] - Market Wire
Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
[ Tue, Jul 24th 2012 ] - Market Wire
Rosetta Genomics and Precision Therapeutics Enter .. Co-Marketing Agreement for miRview mets(2) Assay
[ Tue, Jul 24th 2012 ] - Market Wire
BIOLASE Announces Opening of Corporate Technology and Training Center
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
[ Tue, Jul 24th 2012 ] - Market Wire
Aeterna Zentaris Requests Fast Track Designation .. Diagnostic Test for Adult Growth Hormone Deficien
[ Tue, Jul 24th 2012 ] - Market Wire
Nephros Announces Expansion of U.S. Sales Team
[ Tue, Jul 24th 2012 ] - Market Wire
Reliv International Names Ryan Montgomery President
[ Tue, Jul 24th 2012 ] - Market Wire
Sarepta Therapeutics Announces Significant Clinic .. ter 36 Weeks in Phase IIb Study for the Treatment
[ Tue, Jul 24th 2012 ] - Market Wire
Enzalutamide Granted Priority Review by U.S. FDA .. f Castration-Resistant Prostate Cancer in Patient
[ Tue, Jul 24th 2012 ] - Market Wire
Auxilium Pharmaceuticals to Announce Second Quart .. Conduct Conference Call on Tuesday, July 31, 2012
Mon, July 23, 2012
[ Mon, Jul 23rd 2012 ] - Market Wire
Galapagos Delivers Candidate Drug in Osteoarthritis Alliance With Servier
[ Mon, Jul 23rd 2012 ] - Market Wire
BD Board of Directors Elects Rebecca W. Rimel
[ Mon, Jul 23rd 2012 ] - Market Wire
David Cutler to Resign as President and CEO, Continue as Director
[ Mon, Jul 23rd 2012 ] - Market Wire
Sanofi US Launches Collaborate Activate Innovation Challenge
[ Mon, Jul 23rd 2012 ] - Market Wire
Amgen Announces Webcast of 2012 Second Quarter Financial Results
[ Mon, Jul 23rd 2012 ] - Market Wire
Sarepta Announces Conference Call and Webcast on .. scuss 36-Week 6-Minute Walk Test Results From the
[ Mon, Jul 23rd 2012 ] - Market Wire
Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
[ Mon, Jul 23rd 2012 ] - Market Wire
Ronald L. Chez Files Amended 13D and Letter to the Board
[ Mon, Jul 23rd 2012 ] - Market Wire
Sunshine Heart Announces First Patient Reaches Tw .. Follow-Up Mark for C-Pulse(R) Heart Assist System
[ Mon, Jul 23rd 2012 ] - Market Wire
Implant Sciences Extends Global Distribution Network Into Switzerland
[ Mon, Jul 23rd 2012 ] - Market Wire
InternetArray Appoints StockPlay Director of Marketing
[ Mon, Jul 23rd 2012 ] - Market Wire
Mexico Grants Quick-Med Technologies Additional NIMBUS(R) Patent
[ Mon, Jul 23rd 2012 ] - Market Wire
Trimel Completes Patient Enrolment of CompleoTRT(TM) Phase III Trial
[ Mon, Jul 23rd 2012 ] - Market Wire
Life Technologies Develops Simplified SAME-DAY ST .. ecting Multiple Strains of E. coli in Ground Beef
[ Mon, Jul 23rd 2012 ] - Market Wire
Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call

Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call


Published on 2012-07-23 04:20:45 - Market Wire
  Print publication without navigation


Webcast Alert: Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call -- CARLSBAD, Calif., July 23, 2012 /PRNewswire/ --

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call

[ ]

CARLSBAD, Calif., July 23, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: [ ISIS ]) announces the following webcast:

What:

Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call

When:

Monday, August 6, 2012 at 11:30 a.m. ET / 8:30 a.m. PT

Where:

[ www.isispharm.com ]

How:

Live on the Internet.  Simply log onto our Web site listed above.

Contacts:

Kristina Lemonidis
Director, Investor Relations
(760) 603-2490

Amy Blackley, Ph.D.
Associate Director, Corporate Communications
(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [ www.isispharm.com ].

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]

Contributing Sources